Previous research has indicated that the blockade of H 3 -type histamine receptors may improve attention and memory in normal rodents. The purpose of this study was to determine if ciproxifan, an H 3 receptor antagonist, could alleviate the hyperactivity and cognitive deficits observed in a transgenic mouse model (APP Tg2576 ) of Alzheimer's disease. APP Tg2576 mice displayed significantly greater locomotor activity than wild-type mice, but APP Tg2576 mice provided with daily ciproxifan treatment showed activity levels that did not differ from wild-type mice. In the swim maze, APP Tg2576 mice exhibited significantly longer escape latencies, but the APP Tg2576 mice treated daily with ciproxifan had latencies that were indistinguishable from controls. In probe trials conducted one hour after the last training trial, ciproxifan-treated APP Tg2576 mice spent more time near the previous platform location and made more crossings of this area than did saline-treated APP Tg2576 mice. APP Tg2576 mice also demonstrated a significant impairment in the object recognition task that was reversed by acute treatment with ciproxifan (3.0 mg/kg). These data support the idea that modulation of H 3 receptors represents a novel and viable therapeutic strategy in the treatment of Alzheimer's disease.
Introduction
Over the past decade, preclinical research has identified the H 3 histamine receptor as a possible target for cognitive-enhancing drugs (Bonaventure et al., 2007; Esbenshade, Fox, & Cowart, 2006) . The H 3 receptor exists as a presynaptic autoreceptor that is expressed in relatively high densities in brain regions associated with memory function, such as the frontal cortex and hippocampus (Pillot et al., 2002) . Antagonism (or inverse agonism) of the receptor leads to the release of histamine as well as neurotransmitters involved in learning and memory, such as acetylcholine and dopamine, in the hippocampus and prefrontal cortex (Bacciottini et al., 2002; Clapham & Kilpatrick, 1992; Fox et al., 2005; Ligneau et al., 1998; Ligneau, Perrin, et al., 2007; Medhurst et al., 2007) . Moreover, H 3 antagonists can generate theta rhythms in the brain (Hajós, Siok, Hoffmann, Li, & Kocsis, 2008 ) -a form of activity that predicts the onset of new learning (Berry & Seager, 2001) . On a behavioral level, drugs that act as H 3 antagonists, such as the prototypical imidazole-containing compounds, ciproxifan and thioperamide, have been shown to improve memory function in several tasks -in normal rats and mice, as well as in animals treated with anti-cholinergic or anti-glutamatergic drugs (Bardgett, Points, Kleier, Blankenship, & Griffith, 2010; Bernaerts, Lamberty, & Tirelli, 2004; Fox et al., 2003; Galici et al., 2009; Ligneau et al., 1998) . In addition to their effects on learning and memory, H 3 antagonists have also been shown to modulate the elevating effects of psychostimulants on locomotor activity in rats and mice (Clapham & Kilpatrick, 1994; Fox et al., 2005; Ligneau et al., 2007; Morisset et al., 2002) .
The ability of H 3 antagonists to enhance memory in normal animals and in pharmacological models of memory impairment raises the possibility that such compounds may represent an effective treatment strategy for Alzheimer's disease. As a way of addressing this possibility, we tested the effects of the H 3 antagonist, ciproxifan (Ligneau et al., 1998) , on the learning and memory deficits and hyperlocomotion observed in the amyloid-precursor protein (APP Tg2576 ) transgenic mouse model of Alzheimer's disease. Developed by Hsiao and colleagues (1996) , APP Tg2576 mice express a mutant form of the human APP gene associated with early-onset, familial Alzheimer's disease. These mice exhibit a phenotype that includes the formation of amyloid plaques with increasing age as well as deficits in spatial learning and memory, and object recognition (Hsiao et al., 1996; Taglialatela, Hogan, Zhang, & Dineley, 2009) . Some studies of APP Tg2576 mice have also reported that mutant mice demonstrate elevated locomotor activity (Golub et al., 2008; Tabuchi et al., 2009 ).
In the first study, the effects of ciproxifan on locomotor activity and performance in the swim maze were compared between APP Tg2576 mice and wild-type (WT) littermates of both genders at 1074-7427/$ -see front matter Ó 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.nlm.2010.10.008
